33620 Results

People

  1. Ladanyi
    Ladanyi
  2. Giralt
    Giralt
  3. Motzer
    Motzer
  4. Reuter
    Reuter
  5. Perales
    Perales
  6. Scher
    Scher
  7. Zelenetz
    Zelenetz
  8. Berger
    Berger
  9. Al-Ahmadie
    Al-Ahmadie
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)
  7. Department of Pathology and Laboratory Medicine (5172)
  8. Surgery (4871)
  9. Sloan Kettering Institute Faculty (3826)
  10. Sloan Kettering Institute Postdocs (3612)
  1. "Meeting abstract"
Formats
  1. Meeting Abstract (33620)
Groups
  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)

More Groups

People
  1. Marc Ladanyi (641)
  2. Sergio Giralt (632)
  3. Robert Motzer (574)
  4. Victor Reuter (568)
  5. Miguel-Angel Perales (482)
  6. Howard Scher (463)

More People

Years
  1. 2025 (295)
  2. 2024 (1694)
  3. 2023 (1954)
  4. 2022 (2196)
  5. 2021 (1731)
  6. 2020 (1901)

More Years

Publications
  1. Journal of Clinical Oncology (6252)
  2. Blood (3939)
  3. Laboratory Investigation (1846)
  4. Cancer Research (1822)
  5. International Journal of Radiation Oncology, Biology, Physics (1643)
  6. Modern Pathology (1494)

More Publications

Publishers
  1. American Society of Clinical Oncology (6251)
  2. Elsevier Inc. (4694)
  3. American Society of Hematology (3939)
  4. American Association for Cancer Research (3045)
  5. Nature Publishing Group (2151)
  6. Oxford University Press (2096)

More Publishers

Results (33620)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • IDH2 mutation is associated with favorable outcome among older adults with newly diagnosed acute myeloid leukemia treated with lower-intensity therapy
    Meeting Abstract

    Hoff, F. W.; Huang, Y.; Li Welkie, R.; Swords, R. T.; Traer, E.; Stein, E. M.; Lin, T. L.; Patel, P. A.; Collins, R. H.; Baer, M. R.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Comparative analysis of outcomes with HMA plus venetoclax vs intensive chemotherapy in AML patients harboring very-high risk cytogenetics
    Meeting Abstract

    Aguirre, L. E.; Bewersdorf, J. P.; Liu, Y.; Shallis, R. M.; Boussi, L.; Zucenka, A.; Garciaz, S.; Bystrom, R. P.; Deangelo, D. J.; Stone, R. M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Divergent population dynamics and gene signaling in monocytes distinctly influence responses to CD19-targeted CAR T-cells in relapsed/refractory B-NHL
    Meeting Abstract

    Blumenberg, V.; Kazerani, M.; Straub, T.; Corrado, F.; Borisov, V.; Baumann, S.; Busch, G.; Wulf, J.; Petrera, A.; Rejeski, K.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Validation of dynamic deep learning for the prediction of cancer-associated thrombosis
    Meeting Abstract

    Mantha, S.; Singh, R.; Zwicker, J. I.; Li, A.
    Blood (2024)

    Fulltext@MSK | Save
  • Proteolytic control and therapeutic targeting of oncogenic gene expression in acute myeloid leukemia
    Meeting Abstract

    Uni, M.; Steinberg, A. P.; Slavit, A.; Rha, S.; Cheng, S.; Schmalbrock, L. K.; Su, J.; Ma, J.; McPherson, A.; Mullighan, C. G.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Targeting PERK arm of unfolded protein response helps to eliminate therapy-induced residual senescent-like acute myeloid leukemia cells
    Meeting Abstract

    Poigaialwar, G.; Takao, S.; Chaudhry, S.; Schmalbrock, L. K.; Gupta, V.; Kentsis, A.; Aguirre-Ghiso, J. A.; Konopleva, M.; Sosa, M. S.; Skwarska, A.
    Blood (2024)

    Fulltext@MSK | Save
  • Phase Ib study of PRT543, an oral protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with relapsed or refractory, splicing factor-mutant myeloid malignancies
    Meeting Abstract

    Bewersdorf, J. P.; Mi, X.; Lu, B.; Kuykendall, A. T.; Sallman, D.; Patel, M.; Stevens, D. A.; Philipovskiy, A.; Sutamtewagul, G.; Masarova, L.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Updated comparative efficacy of ciltacabtagene autoleucel versus idecabtagene vicleucel in patients with relapsed or refractory multiple myeloma previously treated with 2-4 prior lines of therapy using a matching-adjusted indirect comparison
    Meeting Abstract

    Lopez-Muñoz, N.; Bar, N.; Diels, J.; van Sanden, S.; Mendes, J.; Lee, S.; Hernando, T.; Lendvai, N.; Patel, N.; Ishida, T.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Idecabtagene vicleucel (Ide-cel) in patients (Pts) with newly diagnosed multiple myeloma (NDMM) with an inadequate response to front-line autologous stem cell transplantation (ASCT): KarMMa-2 cohort 2c extended follow-up
    Meeting Abstract

    Paul, B.; Dhodapkar, M. V.; Alsina, M.; Berdeja, J. G.; Richard, S.; Vij, R.; Leleu, X.; Egan, D. N.; Bergsagel, P. L.; Reshef, R.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Developing an optimal fully-human CD371-targeting IL-18 secreting CART cell for the treatment of acute myeloid leukemia
    Meeting Abstract

    Shahid, S.; Mathew, S.; Souness, S.; Burns, E. R.; Um, J. S.; Yoo, S.; Cai, W.; Pohl, M. A.; Fujino, T.; Zhang, P.; more...
    Blood (2024)

    Fulltext@MSK | Save